A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 3 Recruiting
920 enrolled
KAT6
Phase 2 Recruiting
320 enrolled
OPERA-02
Phase 3 Recruiting
1,000 enrolled
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
399 enrolled
Adjuvant WIDER
Phase 3 Recruiting
1,400 enrolled
EvoPAR-BR01
Phase 3 Recruiting
500 enrolled
CAMBRIA-1
Phase 3 Recruiting
4,300 enrolled
OMAHA-015
Phase 2 Recruiting
250 enrolled
INAVO123
Phase 3 Recruiting
450 enrolled
AVZO-023-1001
Phase 1/2 Recruiting
380 enrolled
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Phase 1/2 Recruiting
180 enrolled
RAMP 301
Phase 3 Recruiting
270 enrolled
IMPULSE
Recruiting
240 enrolled
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Phase 2 Recruiting
60 enrolled
ELEGANT
Phase 3 Recruiting
4,220 enrolled
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
Phase 3 Recruiting
4,800 enrolled
Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
ELEGANCE
Recruiting
2,766 enrolled
OPERA-01
Phase 3 Recruiting
510 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
FourLight-3
Phase 3 Recruiting
1,020 enrolled
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase 1/2 Recruiting
205 enrolled
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Phase 3 Recruiting
240 enrolled
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Phase 1/2 Recruiting
80 enrolled
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
430 enrolled
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Phase 1/2 Recruiting
528 enrolled
CAMBRIA-2
Phase 3 Recruiting
5,500 enrolled
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Phase 1/2 Recruiting
224 enrolled
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Phase 3 Recruiting
350 enrolled